ILD

ERN-LUNG

ERN-LUNG is a service oriented network for patients and healthcare providers in rare respiratory diseases across Europe and wants to be the one-stop information hub.

Our vision is to transfer knowledge and develop expertise through education and training, rather than making patients or experts travel.

We want to support and train a new generation of highly skilled care teams for rare diseases oft e respiratory system in all Member States .

ERN-LUNG, in cooperation with ERS, has made available useful info and learning material (e.g. webinars, publications) for you.

Enjoy the content!

Educational resources

ILD

Congress sessions

State of the art session, Interstitial lung diseases, ERS virtual congress 2020

Download all media

Chronic Hypersensitivity pneumonitis: risks factors and therapeutic options A. Wells (London, United Kingdom)
Genetics in ILDs: what does the future hold? M. Molina Molina (Barcelona, Spain)
Invasive approaches in the diagnosis of ILDs C. Ravaglia (Forlì, Italy)
How systemic inflammatory diseases affect the lung M. Kreuter (Heidelberg, Germany)

Symposium, Severe thoracic sarcoidosis : where do we stand ?, ERS virtual congress 2020

Download all media

Pathogenesis of pulmonary fibrosis in sarcoidosis J. Grutters (Nieuwegein, Netherlands)
Genetic and non-genetic risk factors for severe pulmonary sarcoidosis P. Spagnolo (Padova (PD), Italy)
Severe pulmonary sarcoidosis: definition and risk stratification D. Culver (Cleveland, United States of America)
Management of cardiac sarcoidosis V. Kouranos (London, United Kingdom)

Webinars

COVID-19: Current Challenges in ILD C. Robalo Cordeiro (Coimbra, Portugal), M. Molina Molina (Barcelona, Spain), M. Wijsenbeek (Rotterdam, Netherlands) Tuesday, 21 December 2020
COVID-19 and the management of Interstitial Lung Diseases patients: challenges and recommendations Venerino Poletti (Forli, Italy), Katerina Antoniou (Heraklion, Greece), Elizabeth Renzoni (London, United Kingdom), Sara Tomassetti (Forli, Italy), Athol Wells (London, United Kingdom), Sergio Harari (Milan, Italy), Giorgina Dalpiaz (Bologna, Italy), Bruno Crestani (Paris, France) Thursday, 4 June 2020
COVID-19 in patients with rare diseases of the respiratory system DG Sante (European commission), T.O. F. Wagner (Frankfurt/Main, Germany), I. Fajac (Paris, France), M. Kreuter (Heidelberg, Germany), G. Verleden (Leuven, Belgium), M. Humbert (Paris, France), Heymut Omran (Münster, Germany) Thursday, 30 April 2020

Interactive e-learning content

	Use of radiology in the differential diagnosis of PF-ILDs (pulmonologist/radiologist approach) Toby Maher (St. Albans (Hertfordshire), United Kingdom), S. Walsh (London, United Kingdom) Open

	How to diagnose ILD V. Cottin (Lyon, France), M. Kreuter (Heidelberg, Germany) Open

	ILD and autoimmunity - How to make your diagnosis and manage your patients V. Poletti (Forli, Italy), V. Cottin (Lyon, France) Open

Webcasts

COVID-19: Current Challenges in ILD C. Robalo Cordeiro (Coimbra, Portugal), M. Molina Molina (Barcelona, Spain), M. Wijsenbeek (Rotterdam, Netherlands) Tuesday, 21 December 2020
Management of ILD patients in ICU M. Kokosi (London, United Kingdom)
Selection of ILD patients for ICU and ECMO C. Agerstrand (New York, United States of America)
Pro-con debate: Does it make sense to view rapidly progressive ILD as a distinct clinical entity? - PRO E. Renzoni (London, United Kingdom)
Pro-con debate: Does it make sense to view rapidly progressive ILD as a distinct clinical entity? - CON V. Cottin (Lyon, France)
Benefits of high-flow nasal cannula oxygen therapy on exercise capacity following acute exacerbation in ILD patients S. Arizono (Hamamatsu (Shizuoka), Japan), M. Oomagari (Hamamatsu (Shizuoka), Japan), Y. Yanagita (Hamamatsu (Shizuoka), Japan), H. Machiguchi (Hamamatsu (Shizuoka), Japan), Y. Tawara (Hamamatsu (Shizuoka), Japan), K. Yokomura (Hamamatsu (Shizuoka), Japan)
Effects of nintedanib on progression of ILD in patients with fibrosing ILDs and a progressive phenotype: further analyses of the INBUILD trial K. Flaherty (Ann Arbor, MI, United States of America), A. Wells (London, United Kingdom), V. Cottin (Lyon, France), A. Devaraj (London, United Kingdom), Y. Inoue (Sakai City, Osaka, Japan), L. Richeldi (Rome, Italy), S. Walsh (London, United Kingdom), M. Kolb (Hamilton, Ontario, Canada), D. Koschel (Coswig, Germany), T. Moua (Rochester, MN, United States of America), S. Stowasser (Ingelheim am Rhein, Germany), R. Goeldner (Biberach, Germany), R. Schlenker-Herceg (Ridgefield, CT, United States of America), K. Brown (Denver, CO, United States of America)
Does histology matter in ILD-CTD? V. Poletti (Forlì, Italy)
Interstitial lung disease (ILD) and multicompartment assessment of CTD: where should the respiratory physician begin? C. Denton (London, United Kingdom)
To be or not to be – the uncertainty of PF-ILD M. Kreuter (Heidelberg, Germany), N. Kahn (Heidelberg, Germany), F. Sambataro (Heidelberg, Germany), C. Heussel (Heidelberg, Germany), G. Sambataro (Catania, Italy), C. Vancheri (Catania, Italy), S. Torrisi (Heidelberg, Germany)
ILD S. Harari (Milano (MI), Italy)

Lung ultrasound in children with interstitial lung disease: a pilot study. C. Delestrain (Creteil, France), G. Thouvenin (Creteil, France), N. Richard (Creteil, France), F. Madhi (Creteil, France), L. Berdah (Creteil, France), H. El Jurdi (Creteil, France), A. Clement (Creteil, France), R. Epaud (Creteil, France), H. Corvol (Creteil, France), N. Nathan (Creteil, France)
Assessment of fibrosis in lung biopsies from the European childhood interstitial lung disease (chILD) registry M. Griese (Munich, Germany), E. Seidl (Munich, Germany), K. Knoflach (Munich, Germany), J. Ley-Zaporozhan (Munich, Germany), B. Kammer (Munich, Germany), I. Krueger-Stollfuss (Munich, Germany), S. Reu-Hofer (Wuerzburg, Germany), N. Schwerk (Hannover, Germany), J. Carlens (Hannover, Germany), M. Wetzke (Hannover, Germany), N. Emiralioglu (Ankara, Turkey), N. Kiper (Ankara, Turkey), F. Stehling (Essen, Germany), J. Lange (Warsaw, Poland), K. Krenke (Warsaw, Poland)
Management of ILD patients in ICU M. Kokosi (London, United Kingdom)
Diagnostic procedures in ICU: bronchoscopy and BAL or tissue? C. Ravaglia (Forlì, Italy)
Radiological patterns in ICU: does it matter? N. Sverzellati (Parma (PR), Italy)
Selection of ILD patients for ICU and ECMO C. Agerstrand (New York, United States of America)
The role of cell lines in modelling the type II pneumocyte in interstitial lung disease J. Dickens (Cambridge (Cambridgeshire), United Kingdom)
Lung-on-a -chip: state of the art N. Roldan (Bern, Switzerland)
Using induced pluripotent stem cells to study the type II pneumocyte K. Hurley (Dublin 3, Ireland)
3D tissue culture to study the mechanisms of lung repair in IPF M. Konigshoff (Denver, United States of America)
Microbiome effects on immunity, health and diseases of the lungs K. Antoniou (Heraklion, Greece)
Intrinsic and extrinsic environmental factors in IPF G. Raghu (Seattle, United States of America)
Interstitial lung disease and air pollution: in India and beyond S. Singh (Jaipur (Rajasthan), India)
Air pollution: particle size matters H. Davies (Vancouver, Canada)
Genetic predisposition and the environment M. Molina Molina (Barcelona, Spain)
Combined assessment of regional lung function and morphology using a contrast enhanced Dual-Energy CT protocol: Prospective value of functional imaging biomarkers in longitudinal analysis of patients with Interstitial Lung Disease S. Scharm (Hannover, Germany), S. Dettmer (Hannover, Germany), J. Vogel-Claussen (Hannover, Germany), A. Prasse (Hannover, Germany), L. Knudsen (Hannover, Germany), F. Wacker (Hannover, Germany), J. Fuge (Hannover, Germany), H. Shin (Hannover, Germany)
Methotrexate and risk of Lung disease in Rheumatoid Arthritis: A nationwide population-based cohort study from Denmark S. Burhan Shaker (Copenhagen, Denmark), E. Ibfelt (Copenhagen, Denmark), R. Jacobsen (Copenhagen, Denmark), T. Kopp (Copenhagen, Denmark), R. Cordtz (Aalborg, Denmark), A. Jakobsen (Copenhagen, Denmark), N. Seersholm (Copenhagen, Denmark), L. Dreyer (Aalborg, Denmark)
Beyond the lungs in fibrotic interstitial lung disease: does supplemental O2 improve skeletal muscle oxygenation and fatigue? M. Marillier (Kingston, Canada), A. Bernard (Kingston, Canada), O. Moran-Mendoza (Kingston, Canada), D. O'Donnell (Kingston, Canada), S. Verges (Grenoble, France), J. Neder (Kingston, Canada)
Oxygen enhanced MRI biomarkers of lung function in interstitial lung disease M. Tibiletti (Manchester, United Kingdom), J. Naish (Manchester, United Kingdom), M. Heaton (Manchester, United Kingdom), J. Waterton (Manchester, United Kingdom), P. Hughes (Sheffield, United Kingdom), J. Eaden (Sheffield, United Kingdom), S. Skeoch (Bath, United Kingdom), N. Chaudhuri (Manchester, United Kingdom), I. Bruce (Manchester, United Kingdom), S. Bianchi (Sheffield, United Kingdom), J. Wild (Sheffield, United Kingdom), G. Parker (Manchester, United Kingdom)
B-cell suppressive therapy and monoclonal antibodies in CTD: does one size fit all? D. Kyburz (Basel, Switzerland)
Fibrotic CTD and interstitial pneumonia with autoimmune features (IPAF): immunosuppressive or/and anti-fibrotic treatment? S. Danoff (Baltimore, United States of America)
Does histology matter in ILD-CTD? V. Poletti (Forlì, Italy)
Interstitial lung disease (ILD) and multicompartment assessment of CTD: where should the respiratory physician begin? C. Denton (London, United Kingdom)
Why should we care for the vessels in interstitial lung disease? H. Olschewski (Graz, Austria)
Pleural effusion in Niemann Pick Disease - associated Interstitial Lung Disease E. Boynton (Cambridge, United Kingdom)
Granulomatous lung disease in lymphoma patient after rituximab treatment P. Janowiak (Gdansk, Poland)
Mechanical ventilation in interstitial lung disease M. Dres (Paris, France)